Next Article in Journal
Evaluation of Vitamin D Levels and Response to Therapy of Childhood Migraine
Previous Article in Journal
Invasive and Non-Invasive Fungal Rhinosinusitis—A Review and Update of the Evidence
Article Menu

Export Article

Open AccessArticle

The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population

1
Faculty of Pharmacy, Yarmouk University, Irbid 22110, Jordan
2
Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan
3
Faculty of Medicine, Yarmouk University, Irbid 22110, Jordan
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(7), 320; https://doi.org/10.3390/medicina55070320
Received: 28 May 2019 / Revised: 23 June 2019 / Accepted: 24 June 2019 / Published: 28 June 2019
  |  
PDF [713 KB, uploaded 3 July 2019]
  |  

Abstract

Objectives: The aim of this study was to determine the incidence of metabolic syndrome in patients treated with second-generation antipsychotics (SGAs). Methods: In this retrospective study, we reviewed patients’ electronic medical records (EMRs) of all patients who received one SGA for at least six months, excluding patients who were taking other medications that are associated with significant effect on metabolic syndrome. Relevant clinical information was collected prior to starting the SGA and after six months of continuous use of the same SGA. Results: A total of 91 patients were included in the study. The majority of patients (72%) were diagnosed with schizophrenia. After six months of taking the SGA, 44% of patients experienced elevated systolic pressure, 54.9% had elevated triglyceride, and 31.9% had impaired glucose levels (p value < 0.05). Prior to initiating SGA therapy, 14.3% of patients had metabolic syndrome, while 37.4% had metabolic syndrome after six months of therapy, and it was more prominent in males compared to female patients (p value < 0.05). Conclusion: This study found a strong correlation between SGA use and the appearance of metabolic alterations, such as weight gain, glucose intolerance, and increased triglyceride levels. These findings highlight the importance of assessing metabolic deregulations to minimize SGA associated metabolic abnormalities. View Full-Text
Keywords: metabolic syndrome; second-generation antipsychotics; atypical antipsychotics metabolic syndrome; second-generation antipsychotics; atypical antipsychotics
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Abo Alrob, O.; Alazzam, S.; Alzoubi, K.; Nusair, M.B.; Amawi, H.; Karasneh, R.; Rababa’h, A.; Nammas, M. The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population. Medicina 2019, 55, 320.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicina EISSN 1010-660X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top